Prolonged cell survival in xenografts from human digestive endocrine tumors Abstract #113

Introduction: Gastroenteropancreatic endocrine tumors have the capacity to achieve very large tumor masses despite usually very low proliferative rates. This suggests that neoplastic endocrine cells may have long life spans, implying the development of specific mechanisms able to promote cell survival.
Aim(s): In a first attempt to test this hypothesis, we decided to study the duration of survival of neoplastic endocrine cells obtained from fresh human tumor tissue and transplanted into the nude mouse.
Materials and methods: Fresh tissues were obtained from eight tumors (six primary, two metastatic) obtained from seven patients enrolled after informed consent. There were two pancreatic tumors (one glucagon-positive, one gastrinoma); four were of intestinal origin (all were serotonin positive; one was associated with the carcinoid syndrome); one was a mesenteric lymph node metastasis from a primary tumor located in a Meckel diverticulum. The glucagon-positive pancreatic tumor was classified as a well-differentiated tumor of benign behavior; all other cases were well-differentiated endocrine carcinomas. Immediately after surgical resection, small pieces (2x2x2 mm) of fresh tumor tissue were transplanted subcutaneously between the scapulae under anaesthesia into 4- to 5-week-old female Balb/c nude mice (eight mice per tumor). Animals were sacrificed one, two, four and six months after grafting; tumor tissues were either fixed in buffered formalin or frozen in liquid nitrogen for further histological and immunohistochemical techniques. When possible, tumor samples derived from grafted tumors were retransplanted.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Colette Roche

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2895 Survival Related to Treatment of Patients with Metastatic Neuroendocrine Lung Tumors Treated in a Brazilian Center
Introduction: Well-differentiated Neuroendocrine Pulmonary Tumors (NETp) are morphologically classified as Typical (TC) and Atypical Carcinoid (AC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hugo Tanaka
#2908 Re-Cellularised Human Pancreas 3D Scaffolds as a Novel Model for Biomarker Discovery in Pancreatic Neuroendocrine Tumours (pNETs)
Introduction: The lack of preclinical models of pNETs has challenged identification of tissue specific biomarkers of disease. Culturing cancer cells in their native tissue enables the close study of cell-ECM interaction and tissue remodelling. The biological products of such interactions can form a basis for discovery of novel biomarkers of the disease, and were previously linked with a range of inflammatory and malignant conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD student & CR Alexander Ney
#2986 Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: DVM Tiago B Gaspar
#602 Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas
Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Colette Roche
Authors: Bollard J, Couderc C, Blanc M, Poncet G, ...
#1707 Implication of Neuropilin-2 in the Progression of Small Intestinal Neuroendocrine Tumors: Towards a Promising Therapeutic Target?
Introduction: Small intestinal neuroendocrine tumors (siNETs) are rare tumors that raise several clinical and therapeutic challenges. Current treatments are not efficient, in part because of a poor understanding of their mechanisms of progression. We recently highlighted some axon guidance molecules (AGMs) that might be implicated in the progression of siNETs. Among them, we are currently focusing our efforts on the semaphorin 3F receptor neuropilin-2 (NRP2).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D Julien Bollard
Keywords: siNETs, progression, NRP2